Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Cancer treatments Stories

2013-12-05 12:29:29

A REAL OPTION FOR STANDARD THERAPY-RESISTANT CANCERS SCOTTSDALE, Ariz., Dec. 5, 2013 /PRNewswire/ -- In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers...

2013-12-05 08:28:54

PRINCETON, N.J., Dec. 5, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator...

2013-12-04 08:29:53

WOODCLIFF LAKE, N.J., Dec. 4, 2013 /PRNewswire/ -- Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer Symposium. The meeting will be held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, TX. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the...

2013-11-25 16:27:01

REDWOOD CITY, Calif. and CRAIGAVON, United Kingdom, Nov. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) and ALMAC GROUP Ltd jointly announced today that Genomic Health will exclusively license Almac Group's technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. Such a test would...

2013-11-25 15:15:08

Glioblastoma is one of the most ominous brain tumors. Despite aggressive surgery, radiation and chemotherapy the outcome of this disease is almost always fatal. A UZH research team has now achieved success with a novel form of treatment that involves encouraging the body’s own immune system to recognise and eliminate cancer cells in the brain. Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat...

2013-11-23 23:03:40

The Greenville Health System’s Human Performance Laboratory – expected to open in January 2014 – is the first HPL in the nation to be fully embedded into a cancer research and treatment program. Greenville, S.C. (PRWEB) November 23, 2013 The Greenville Health System’s Human Performance Laboratory – expected to open in January 2014 – is the first HPL in the nation to be fully embedded into a cancer research and treatment program. The HPL, which already is working with a...

2013-11-23 23:01:53

A new report published in the Proceedings of the National Academy of Science (PNAS) Early Edition details a study funded in part by the National Foundation for Cancer Research, which indicates magnetic resonance (MR) imaging may be able to discern which patients will benefit more from anti-angiogenic drugs. Bethesda, MD (PRWEB) November 23, 2013 A new report published in the Proceedings of the National Academy of Science (PNAS) Early Edition details a study funded in part by the National...

2013-11-21 08:28:39

The inovitro laboratory research system enables scientists to study the effects of Tumor Treating Fields in cancer cells. NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Today, Novocure announced the launch of the inovitro, a propriety plug-and-play laboratory research system that allows scientists to apply Tumor Treating Fields (TTFields) to cancer cells in the lab. (Photo: http://photos.prnewswire.com/prnh/20131121/NY21742 ) "With the inovitro, researchers can, for the first time,...

2013-11-19 23:32:51

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new scientific breakthrough that claims the Christmas Fern plant can shrink brain tumors. New York, NY (PRWEB) November 19, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on new breakthrough cancer research linked to the Christmas Fern plant. According to a November 13, 2013 article published by WTNH.com titled, “Fern...

2013-11-19 12:29:24

HAIFA, Israel, Nov. 19, 2013 /PRNewswire/ -- Novocure announced today that the first patients have enrolled in the EF-21 Study, a prospective randomized clinical study of NovoTTF(TM) Therapy for patients with brain metastases from non-small cell lung carcinoma (NSCLC) cancer. NovoTTF Therapy is an anti-mitotic treatment delivered continuously throughout the day by the NovoTTF-100A System. "The EF-21 Study builds on extensive preclinical research on the effect of NovoTTF Therapy in...